Key Insights

Highlights

No notable highlights available yet

Clinical Risk Assessment

Based on trial outcomes

High Risk

Score: 90/100

Termination Rate

25.0%

1 terminated out of 4 trials

Success Rate

0.0%

-86.5% vs benchmark

Late-Stage Pipeline

25%

1 trials in Phase 3/4

Results Transparency

0%

2 of 0 completed with results

Key Signals

2 with results0

Data Visualizations

Phase Distribution

4Total
Not Applicable (1)
P 2 (2)
P 3 (1)

Trial Status

Active Not Recruiting2
Terminated1
Recruiting1

Clinical Trials (4)

Showing 4 of 4 trials
NCT04444921Phase 3Active Not Recruiting

EA2176: Phase 3 Clinical Trial of Carboplatin and Paclitaxel +/- Nivolumab in Metastatic Anal Cancer Patients

NCT02314169Phase 2Active Not Recruiting

Nivolumab With or Without Ipilimumab in Treating Patients With Refractory Metastatic Anal Canal Cancer

NCT04221893Not ApplicableRecruiting

Radiation Therapy for the Treatment of Metastatic Gastrointestinal Cancers

NCT03439085Phase 2Terminated

DNA Plasmid-encoding Interleukin-12/HPV DNA Plasmids Therapeutic Vaccine INO-3112 and Durvalumab in Treating Patients With Recurrent or Metastatic Human Papillomavirus Associated Cancers

Showing all 4 trials

Research Network

Activity Timeline